Información del producto
JNJ-1661010 is a non-selective, orally active, potent and selective small molecule antagonist of the neurokinin-1 receptor (NK1R). It has been shown to inhibit cancer cell invasion. JNJ-1661010 also inhibits the activation of cb2 receptors by endocannabinoids, which may be useful for the treatment of skin cancer. This drug also demonstrates inhibitory properties on inflammatory diseases and autoimmune diseases. JNJ-1661010 is metabolized in humans by hydroxylation and/or amide hydrolysis. The metabolic products are then excreted in urine and feces.
Propiedades químicas
Consulta técnica sobre: 3D-GCB13629 JNJ-1661010
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.
